Kalaris Therapeutics
KLRS----
About
Kalaris Therapeutics
KLRS.US
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc.
Profile
- Company Name
- Kalaris Therapeutics, Inc.
- Market
- NasdaqGM
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- kalaristx.com